KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors
01 May, 2021
– Icosavax closed a $100m Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, and Surveyor Capital (a Citadel company).
– A previously announced funding from Open Philanthropy was included in this round.
– The proceeds of the financing will support the development of Icosavax’s bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine program through initial clinical studies, continued evaluation of its SARS-CoV-2 vaccine candidate, and further expansion of the company’s pipeline of VLP vaccine candidates focused on protecting older adults from life-threatening respiratory diseases.